Pharmaceutical industry
GW Pharmaceuticals has secured an $8.6m deal with a US investor, Polygon Investment Partners, to advance its pioneering cannabis-based drug Sativex in the United States. The deal will enable GW to develop Sativex in the US, with the company hoping to file for approval in two or three years&
Pharmaceutical industry
Biotech development in 2006 was characterized by a lack of significant regulatory progress, with many proposed regulations from 2005 failing to materialize. Michael Fernandez, executive director of the Pew Initiative on Food and Biotechnology, noted that the same regulations were still on the agenda as the previous year, with no
Drugs
The Food and Drug Administration has granted conditional approval to Vivitrol, a much-anticipated drug made by Alkermes Inc. that targets alcoholism. The medication, which is a once-a-month injection of naltrexone, has shown promise in reducing heavy drinking in patients undergoing counseling. While the FDA has requested additional scientific data and
Pharmaceutical industry
Nutra Pharma Corp., a biotechnology holding company, has announced the engagement of Isserman Consulting to lead a comprehensive press communications and shareholder relations campaign. The company, which owns rights to intellectual property related to the development of drugs for HIV and Multiple Sclerosis, aims to gain recognition for its accomplishments
Pharmaceutical industry
Carrington Laboratories' subsidiary, DelSite Biotechnologies, has secured a significant intellectual property advantage in the field of controlled-release drug delivery technologies. The European Patent Office has issued European Patent No. EP 1 086 141 B1 for "Aloe Pectins," a patent that broadly covers the use of DelSite'
Drugs
Sangamo BioSciences, Inc. has completed subject enrollment and treatment in its phase I study of SB-509, a novel ZFP therapeutic designed to treat diabetic neuropathy by upregulating the expression of vascular endothelial growth factor (VEGF). The study, which evaluated the safety of SB-509 in diabetics with mild to moderate diabetic
Pharmaceutical industry
Satraplatin, an investigational drug and Spectrum Pharmaceuticals' lead drug candidate, is being evaluated in a phase II study for treating metastatic breast cancer patients who have received no more than one prior chemotherapy treatment regimen. The open-label, multicenter study is being managed by US Oncology and will enroll 80
Pharmaceutical industry
A new phase II study has been opened for accrual, evaluating satraplatin, a drug candidate from GPC Biotech, AG, (GPCB), in patients with metastatic breast cancer who have received no more than one prior chemotherapy treatment regimen. The study is being managed by US Oncology, a healthcare-services network dedicated to
Pharmaceutical industry
The U.S. Food & Drug Administration has approved Tarceva (erlotinib) in combination with gemcitabine chemotherapy for the treatment of advanced pancreatic cancer in patients who have not received previous chemotherapy. Tarceva, a once-daily oral tablet, has shown a significant improvement in overall survival when added to gemcitabine chemotherapy as
Pharmaceutical industry
The European Commission has authorized the treatment of severe allergic asthma with Xolair (omalizumab) in all 25 European Union member states. Developed by Tanox, Inc., Genentech, and Novartis Pharma AG, Xolair is a humanized therapeutic antibody that targets IgE, a key cause of inflammation and symptoms in allergic diseases. The
Drugs
Researchers presented clinical data at the Chemotherapy Foundation Symposium XXIII on Abraxane, a chemotherapy treatment that targets difficult-to-treat tumors. The studies showed high response rates in various types of cancer, including non-small cell lung cancer, metastatic malignant melanoma, and head and neck cancer. The treatment works by exploiting a protein
Drugs
Introgen Therapeutics, Inc. (INGN) has unveiled data on a novel mechanism of action for its therapy, INGN 241, which targets the formation of new blood vessels in tumors, a process called angiogenesis. This mechanism is crucial for tumors to establish a sufficient supply of oxygen and nutrients, leading to tumor
